Last reviewed · How we verify
bonviva
bonviva is a Small molecule drug developed by Alvogen Korea. It is currently in Phase 1 development for Hypercalcemia, Postmenopausal osteoporosis. Also known as: DP-R206 : DP11012, bonviva : B1184B01.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | bonviva |
|---|---|
| Also known as | DP-R206 : DP11012, bonviva : B1184B01 |
| Sponsor | Alvogen Korea |
| Target | Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | Phase 1 |
Approved indications
- Hypercalcemia
- Postmenopausal osteoporosis
Common side effects
- Back Pain
- Pain in Extremity
- Dyspepsia
- Diarrhea
- Headache
- Myalgia
- Arthralgia
- Abdominal Pain
- Bronchitis
- Pneumonia
- Upper Respiratory Infection
- Infection
Key clinical trials
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate (PHASE2)
- Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America
- Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy. (NA)
- Post-fracture Medication and Mortality
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bonviva CI brief — competitive landscape report
- bonviva updates RSS · CI watch RSS
- Alvogen Korea portfolio CI
Frequently asked questions about bonviva
What is bonviva?
What is bonviva used for?
Who makes bonviva?
Is bonviva also known as anything else?
What development phase is bonviva in?
What are the side effects of bonviva?
What does bonviva target?
Related
- Target: All drugs targeting Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase
- Manufacturer: Alvogen Korea — full pipeline
- Therapeutic area: All drugs in Bone
- Indication: Drugs for Hypercalcemia
- Indication: Drugs for Postmenopausal osteoporosis
- Also known as: DP-R206 : DP11012, bonviva : B1184B01
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing